Dashboard
Manage Tickers

CRVOCervoMed Inc.

Nasdaq www.cervomed.com


$ 18.50 $ 1.22 (7.16 %)    

Friday, 16-Aug-2024 15:59:49 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 475.24 $ 0.61 (0.13 %)
DIA $ 406.80 $ 0.86 (0.21 %)
SPY $ 554.24 $ 1.24 (0.22 %)
TLT $ 97.41 $ 0.34 (0.35 %)
GLD $ 231.90 $ 5.08 (2.24 %)
$ 18.26
$ 17.61 x 100
-- x --
-- - --
$ 4.28 - $ 26.38
93,944
na
150.71M
$ 0.72
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-09-2024 06-30-2024 10-Q
2 05-14-2024 03-31-2024 10-Q
3 03-29-2024 12-31-2023 10-K
4 11-13-2023 09-30-2023 10-Q
5 08-08-2023 06-30-2023 10-Q
6 05-15-2023 03-31-2023 10-Q
7 03-24-2023 12-31-2022 10-K
8 11-14-2022 09-30-2022 10-Q
9 08-12-2022 06-30-2022 10-Q
10 05-12-2022 03-31-2022 10-Q
11 03-18-2022 12-31-2021 10-K
12 11-10-2021 09-30-2021 10-Q
13 08-11-2021 06-30-2021 10-Q
14 05-07-2021 03-31-2021 10-Q
15 03-17-2021 12-31-2020 10-K
16 11-12-2020 09-30-2020 10-Q
17 08-07-2020 06-30-2020 10-Q
18 05-11-2020 03-31-2020 10-Q
19 03-17-2020 12-31-2019 10-K
20 11-08-2019 09-30-2019 10-Q
21 08-08-2019 06-30-2019 10-Q
22 05-09-2019 03-31-2019 10-Q
23 03-19-2019 12-31-2018 10-K
24 11-13-2018 09-30-2018 10-Q
25 08-10-2018 06-30-2018 10-Q
26 05-10-2018 03-31-2018 10-Q
27 04-02-2018 12-31-2017 10-K
28 11-13-2017 09-30-2017 10-Q
29 08-14-2017 06-30-2017 10-Q
30 05-15-2017 03-31-2017 10-Q
31 03-31-2017 12-31-2016 10-K
32 11-14-2016 09-30-2016 10-Q
33 08-15-2016 06-30-2016 10-Q
34 05-16-2016 03-31-2016 10-Q
35 03-25-2016 12-31-2015 10-K
36 11-12-2015 09-30-2015 10-Q
37 08-12-2015 06-30-2015 10-Q
38 05-11-2015 03-31-2015 10-Q
39 04-03-2015 12-31-2014 10-K
40 11-12-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

cervomed-q2-2024-eps-027-beats-042-estimate-sales-329m-beat-208m-estimate
CervoMed Q2 2024 EPS $(0.27) Beats $(0.42)...
08/12/2024 12:07:48

CervoMed (NASDAQ:CRVO) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.42) by 3...

cervomed-presents-on-plasma-biomarker-data-consistent-with-neflamapimod-impacting-the-underlying-disease-process-in-patients-with-dementia-with-lewy-bodies-at-aaic-2024
CervoMed Presents On Plasma Biomarker Data...
07/29/2024 12:13:24

- Baseline data from the AscenD-LB Phase 2a trial in DLB demonstrated that plasma glial fibrillary acidic protein (GFAP) was hi...

morgan-stanley-initiates-coverage-on-cervomed-with-overweight-rating-announces-price-target-of-35
Morgan Stanley Initiates Coverage On Cervo...
07/26/2024 10:00:23

Morgan Stanley analyst Jeffrey Hung initiates coverage on CervoMed (NASDAQ:CRVO) with a Overweight rating and announces Pric...

canaccord-genuity-maintains-buy-on-cervomed-maintains-65-price-target
Canaccord Genuity Maintains Buy on CervoMe...
07/25/2024 13:09:33

Canaccord Genuity analyst Sumant Kulkarni maintains CervoMed (NASDAQ:CRVO) with a Buy and maintains $65 price target.

brookline-capital-initiates-coverage-on-cervomed-with-buy-rating-announces-price-target-of-63
Brookline Capital Initiates Coverage On Ce...
07/08/2024 17:50:08

Brookline Capital analyst Tyler Bussian initiates coverage on CervoMed (NASDAQ:CRVO) with a Buy rating and announces Price T...

cervomed-announces-addition-to-russell-2000-and-russell-3000-indexes
CervoMed Announces Addition To Russell 200...
06/24/2024 12:03:09

CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, to...

cervomed-completes-enrollment-in-phase-2b-rewind-lb-clinical-trial-of-neflamapimod-for-the-treatment-of-patients-with-dementia-with-lewy-bodies
CervoMed Completes Enrollment In Phase 2b ...
06/11/2024 12:27:14

- Topline data expected in December 2024 - - Phase 2b design optimized for success; clear path to market in this high value ind...

jones-trading-initiates-coverage-on-cervomed-with-buy-rating-announces-price-target-of-70
Jones Trading Initiates Coverage On CervoM...
05/29/2024 10:38:38

Jones Trading analyst Soumit Roy initiates coverage on CervoMed (NASDAQ:CRVO) with a Buy rating and announces Price Target o...

why-virios-therapeutics-shares-are-trading-lower-by-around-48-here-are-other-stocks-moving-in-mondays-mid-day-session
Why Virios Therapeutics Shares Are Trading...
05/20/2024 17:28:52

cervomed-names-william-elder-as-chief-financial-officer-effective-june-1-2024
CervoMed Names William Elder As Chief Fina...
05/20/2024 12:04:47

CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, to...

cervomed-q1-eps-041-misses-039-estimate-sales-235m-beat-135m-estimate
CervoMed Q1 EPS $(0.41) Misses $(0.39) Est...
05/15/2024 12:14:46

CervoMed (NASDAQ:CRVO) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.39) by...

disney-to-rally-around-10-here-are-10-top-analyst-forecasts-for-monday
Disney To Rally Around 10%? Here Are 10 To...
04/08/2024 12:00:36

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

canaccord-genuity-maintains-buy-on-cervomed-raises-price-target-to-65
Canaccord Genuity Maintains Buy on CervoMe...
04/08/2024 11:37:59

Canaccord Genuity analyst Sumant Kulkarni maintains CervoMed (NASDAQ:CRVO) with a Buy and raises the price target from $50 t...

cervomed-announces-private-placement-financing-including-50m-financing-upfront-with-up-to-an-additional-994m-tied-to-exercise-of-warrants
CervoMed Announces Private Placement Finan...
03/28/2024 12:35:08

12-health-care-stocks-moving-in-thursdays-intraday-session
12 Health Care Stocks Moving In Thursday's...
03/21/2024 17:31:11

cervomed-announces-presentation-of-biomarker-data-from-the-ascend-lb-phase-2a-trial-and-preclinical-data-supporting-potential-of-neflamapimod-in-tau-mediated-disease-at-adpd--2024
CervoMed Announces Presentation Of Biomark...
03/05/2024 13:01:13

- Neflamapimod led to significant reduction compared to placebo in plasma levels of glial fibrillary acidic protein (GFAP) - Ne...

canaccord-genuity-initiates-coverage-on-cervomed-with-buy-rating-announces-price-target-of-50
Canaccord Genuity Initiates Coverage On Ce...
02/15/2024 12:18:23

Canaccord Genuity analyst Sumant Kulkarni initiates coverage on CervoMed (NASDAQ:CRVO) with a Buy rating and announces Price...

cervomed-publishes-results-from-ascend-lb-phase-2a-trial-evaluating-treatment-of-neflamapimod-in-dementia-with-lewy-bodies
CervoMed Publishes Results From AscenD-LB ...
02/12/2024 13:08:03

-Integrated summary of all previously published Phase 2a clinical results, together with the first peer reviewed publication of...

cervomed-appoints-joshua-boger-as-board-chair
CervoMed Appoints Joshua Boger As Board Chair
02/07/2024 13:35:27

Dr. Boger is the founder, and retired CEO and Board Chair, of Vertex Pharmaceuticals CervoMed on track to complete enrollment i...

12-health-care-stocks-moving-in-mondays-pre-market-session
12 Health Care Stocks Moving In Monday's P...
11/06/2023 13:06:45

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION